ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more flexible, data-driven approaches that integrate prior knowledge, reduce sample ...
Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Good morning, and welcome to Ocugen's webcast to discuss data from the first half of patients completing 1 year since ...
Phase 2 trial results show XPro™ benefits cognition in certain early Alzheimer's patients, pending further data analysis and FDA designation. INmune Bio Inc. announced results from its Phase 2 MINDFuL ...
Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...
A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma. Phase I dose escalation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results